Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
May 26, 2022 08:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Hosts Inaugural Investor Day
May 16, 2022 16:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), will host its Inaugural Investor Day at the Nasdaq MarketSite on Tuesday, May 17,...
Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting
May 16, 2022 08:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients
May 13, 2022 08:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer
May 11, 2022 08:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus to Present at the UBS Global Healthcare Conference
May 10, 2022 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results
April 29, 2022 07:07 ET
|
Lantheus Holdings, Inc.
Worldwide revenue of $208.9 million for the first quarter 2022, representing an increase of 125.8% from the prior year period GAAP net income of $43.0 million for the first quarter 2022, compared to...
Lantheus Holdings to Host First Quarter 2022 Earnings Conference Call and Webcast on April 29, 2022 at 8:00 a.m. Eastern Time
April 15, 2022 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., April 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on...
Lantheus Appoints Jean-Claude Provost, MD as Interim Chief Medical Officer
April 04, 2022 08:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development
March 29, 2022 08:00 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...